Navigation Links
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/5/2008

Interim Phase 1 Data Presented at International Conference on Malignant

Lymphomas Shows Dose Dependent Single Agent Activity

BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data(1) with the CD19-specific BiTE antibody show that all seven patients in the highest dose cohort tested so far (0.06 mg/m2/day) achieved complete or partial responses.

In the study, relapsed, incurable non-Hodgkin's lymphoma (NHL) patients who previously failed a median of three (and up to 12) conventional therapies were treated with increasing doses of blinatumomab (MT103/MEDI-538) for four to eight weeks. Dose-dependent clinical activity was observed. At the recently completed cohort of 0.06 mg/m2 per day, seven out of seven patients showed either complete or partial responses. Remissions in this and the previous dose cohort continue in all patients, with the longest remission ongoing for more than one year. Most frequent side effects observed so far were lymphopenia, pyrexia, and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes, and central nervous system events, all of which were fully reversible.

"The high response rate and apparently durable remissions in this heavily pre-treated patient population support blinatumomab as a single agent therapy with the potential for accelerated development," said Micromet's Senior Vice President and Chief Medical Officer, Dr. Carsten Reinhardt.

"ICML brings together thousands of the world's leading specialists and researchers to present the latest adva
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
5. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...heNetherlandsandJOHANNESBURG,November25/PRNewswire...Discoveryannouncedtoday,thattheyhavesignedacollabo...ces. , Pyxis,sworldclasscomputationalchemistr...a,sservicedivisiontoprovidemedicinaland,syntheticc...nternationalclientnetwork.iThembaPharmaceuticalsan...
(Date:11/24/2009)...RGH,Nov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBe...anautoaccident,wasactuallyfullyconsciousandawakedu...egment.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoil...itionscanunlockcommunication. ,, WHEN:GoodMorni... www.dynavoxtech.com ,, WHO:RomHoubenswasa...
(Date:11/24/2009)...O,Nov.24/PRNewswire-FirstCall/--AnadysPharmaceutic...sentatthe21stAnnualPiperJaffrayHealthcareConferenc...).TheconferenceisbeingheldatTheNewYorkPalaceHotel....erofAnadys,willprovideanoverviewofAnadysanditsclin...corporatepresentationwillbesimultaneouslywebcastan...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Alan Stein D D S Opens His Doors and Empties His Pockets 49215 1Alan Stein D D S Opens His Doors and Empties His Pockets 49215 2Commercial Medical and Pharmacy Benefit Enrollment Down in New York 49212 1Commercial Medical and Pharmacy Benefit Enrollment Down in New York 49212 2Hartford grants increase support for geriatric social work training 49209 1Hartford grants increase support for geriatric social work training 49209 2Hartford grants increase support for geriatric social work training 49209 3
...ry clinical laboratory possesses one essential dev...del, refrigerated or non-cooled, but this apparatu...quid specimens by creating spin-induced high g-for...sis and research applications. For all this utilit...viding trouble-free service for many thousands of ...
...s infectious mononucleosis (IM), is one of the mos...most people become infected with EBV sometime duri...5 percent of adults between 35 and 40 years of age...including the U.S., infection with EBV most often ...ing infectious mononucleosis in 35 percent to 50 p...
Other Medicine Technology:Bench-Top Centrifuges--Basic Tools for the Small Lab 2Bench-Top Centrifuges--Basic Tools for the Small Lab 3Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 2Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies 3
(Date:11/25/2009)...ire-USNewswire/--WhenmostpeopleheartheacronymTMJ,t...patientsthehelptheyneed.TMJstandsfortheTemporal-Ma...s/connectswithyourskull(temporalbone). ,, Themo...nwithchewing,clickingorpoppingofthejaw.Butmanyothe...adaches,fatigue,sleepdisturbances,irritability,alo...
(Date:11/25/2009)...-SentinelleMedicalInc.,aleadingmanufacturerofbreas...suiteofnewleadingedgeclinicalapplicationsonitsAegi...iologicalSocietyofNorthAmerica(RSNA)annualmeetingi...licationsleveragetheuniquehighqualityimagesgenerat...rtmultipleimagingmodalitiesformulti-parametricasse...
(Date:11/25/2009)...wire/--TheBayAreaAirQualityManagementDistrictisiss... Alert forThursday,November26,2009whichbansbu...bothindoorsandoutdoors. ,, "Cold,stillweatherwi...kBroadbent,executiveofficeroftheAirDistrict."We,re...ghborsandfellowcommunitymembersthisThanksgiving,an...
(Date:11/25/2009)...ew out of a collaboration between UCLA engineers a...nearly 10 million Americans who suffer from periph...ning of the arteries, peripheral arterial disease,...narrowed arteries reduce blood flow to the limbs. ...r disease, heart attack and stroke, and its progre...
(Date:11/25/2009)...on and treatment clinics to resume Monday, Nov. 30...mber 25, 2009 -- Centegra Health System is continu...shots at four Centegra Primary Care (CPC) vaccinat...arrived. The clinics are at CPC sites in Huntley, ...en as follows: ,   From 4:30 to 7:30 p...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
..., July 3 Michael J. Fitzpatrick,executive directo...), the,nation,s largest grassroots organization de...families affected by mental illnesses, has issued ...ychiatric,ward at Kings County Hospital in Brookly...
... IRELAND In response to the global health crisis,...creditation movements in global health promotion, ...ord last week on what should comprise the domains ...National University of Ireland, Galway, who serves...
... prevent spread of disease in developing countries...althDay News) -- In developing countries where br...he risk of disease transmission through breast mil... , But that hope is theoretical, because the formu...
...URG, Pa., July 3 Vibra Healthcare, LLC,("Vibra") ...ion of two,specialty hospitals in Southern Califor...bilitation Hospital of San Diego (a 110-bed freest...habilitation Hospital)., Brad Hollinger, Founder,...
..., R.I., July 3 The CVS Caremark Charitable,Trust,...nnounced today that,it has donated $100,000 to the...roughout the more than 80 counties in Iowa declare...nated,over $35,000 in product and services to thes...
...N.J., July 3 Barr Pharmaceuticals,Inc. (NYSE: BR...onference,Call at 8:30AM Eastern time on Thursday,...nd quarter of calendar 2008, ended June 30, 2008. ...le,from 10:30AM Eastern time on August 7 through 1...
Other Medicine News:Health News:Kings County Death: NAMI Calls for Criminal Probe; Survey Shows Psychiatric Emergency Room Delays Are National Problem 2Health News:Accord on core competency, standards and quality assurance in health promotion and education 2Health News:Freeze-Dried Formula May Block HIV Virus in Breast Milk 2Health News:CVS/pharmacy Delivers Disaster Relief in Iowa Communities Impacted by Recent Flooding 2Health News:Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008 2Health News:Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008 3
BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q70-CAB-ERB
...ve seats and large backrests with lumbar support &...ts, and casters and glides. • Choose the BE S...ents including: industry, education, laboratory, c... • With cast aluminum base • unit standa...
...ve seats and large backrests with lumbar support &...ts, and casters and glides. • Choose the BE S...ents including: industry, education, laboratory, c... • With cast aluminum base • unit standa...
BET/1P-ERB - Tubular Base - Model 1P61-ERB
Medicine Products: